US pharma major Johnson & Johnson (NYSE: JNJ) has won US approval for Tremfya (guselkumab) in the treatment of adults with ...

Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16th edition of Skin Academy, a premier conference for healthcare professionals in the field of dermatology. This ...

The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated ...

Psoriasis organizations ... patients with lived experience, and information from top institutions. Susan Bard, MD, is a clinical instructor in the department of dermatology at Weill Cornell ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

Lower doses of a common antibiotic can curb hair loss caused by a rare skin condition, a new study says. The antibiotic ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Patients with specific dermatological immune-mediated inflammatory diseases are not at increased risk of developing severe COVID-19.

A systematic review revealed that patients with psoriasis have a significantly higher prevalence of onychomycosis than those without psoriasis.